XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
XOMA Royalty Corporation (NASDAQ: XOMA) has acquired BioInvent International's future royalty and milestone rights for mezagitamab (TAK-079) in a deal worth up to $30 million. The transaction includes $20 million paid at closing and an additional $10 million contingent upon mezagitamab receiving FDA marketing approval for IgA nephropathy.
With this acquisition and its existing entitlements, XOMA will receive up to $16.25 million in milestones from Takeda and mid-single digit royalties on future mezagitamab commercial sales. Takeda is currently conducting a Phase 3 clinical trial for mezagitamab in immune thrombocytopenia (ITP) patients. The drug is a fully human IgG1 monoclonal antibody targeting CD38-expressing cells, with potential to become best-in-class in its category.
XOMA Royalty Corporation (NASDAQ: XOMA) ha acquisito i diritti futuri di royalty e milestone su mezagitamab (TAK-079) da BioInvent International, in un accordo del valore fino a 30 milioni di dollari. La transazione prevede un pagamento iniziale di 20 milioni di dollari e ulteriori 10 milioni di dollari condizionati all'approvazione da parte della FDA per la commercializzazione del farmaco nella nefropatia da IgA.
Con questa acquisizione e i diritti già detenuti, XOMA potrà ricevere fino a 16,25 milioni di dollari in milestone da Takeda e royalty a una cifra media a una sola cifra percentuale sulle future vendite commerciali di mezagitamab. Takeda sta attualmente conducendo uno studio clinico di Fase 3 su mezagitamab in pazienti con porpora trombocitopenica immune (ITP). Il farmaco è un anticorpo monoclonale IgG1 completamente umano che mira alle cellule che esprimono CD38, con il potenziale di diventare il migliore della sua categoria.
XOMA Royalty Corporation (NASDAQ: XOMA) ha adquirido los derechos futuros de regalías y hitos de BioInvent International para mezagitamab (TAK-079) en un acuerdo valorado en hasta 30 millones de dólares. La transacción incluye un pago inicial de 20 millones de dólares y otros 10 millones de dólares condicionados a la aprobación de la FDA para la comercialización de mezagitamab en nefropatía por IgA.
Con esta adquisición y sus derechos existentes, XOMA recibirá hasta 16,25 millones de dólares en hitos de Takeda y regalías de un dígito medio bajo sobre las futuras ventas comerciales de mezagitamab. Takeda está actualmente realizando un ensayo clínico de Fase 3 para mezagitamab en pacientes con trombocitopenia inmune (ITP). El medicamento es un anticuerpo monoclonal IgG1 totalmente humano que se dirige a células que expresan CD38, con potencial para convertirse en el mejor de su clase.
XOMA Royalty Corporation (NASDAQ: XOMA)는 BioInvent International의 메자가티맙(TAK-079)에 대한 미래 로열티 및 마일스톤 권리를 최대 3천만 달러 규모의 계약으로 인수했습니다. 이 거래에는 계약 체결 시 2천만 달러 지급과, 메자가티맙이 IgA 신병증에 대해 FDA 마케팅 승인을 받을 경우 추가 1천만 달러가 포함됩니다.
이번 인수와 기존 권리를 통해 XOMA는 Takeda로부터 최대 1,625만 달러의 마일스톤과 향후 메자가티맙 상업 판매에 대한 중간 한 자릿수 로열티를 받게 됩니다. Takeda는 현재 면역 혈소판 감소증(ITP) 환자를 대상으로 메자가티맙의 3상 임상 시험을 진행 중입니다. 이 약물은 CD38을 발현하는 세포를 표적으로 하는 완전 인간 IgG1 단클론 항체로, 해당 분야에서 최고 수준의 약물이 될 잠재력을 지니고 있습니다.
XOMA Royalty Corporation (NASDAQ : XOMA) a acquis les droits futurs de redevances et de jalons de BioInvent International pour le mezagitamab (TAK-079) dans un accord d'une valeur pouvant atteindre 30 millions de dollars. La transaction comprend un paiement initial de 20 millions de dollars à la clôture, ainsi qu'un paiement supplémentaire de 10 millions de dollars conditionné à l'approbation marketing par la FDA du mezagitamab pour la néphropathie à IgA.
Avec cette acquisition et ses droits existants, XOMA recevra jusqu'à 16,25 millions de dollars en jalons de Takeda ainsi que des redevances à un chiffre médian sur les futures ventes commerciales de mezagitamab. Takeda mène actuellement un essai clinique de phase 3 du mezagitamab chez des patients atteints de thrombocytopénie immunitaire (ITP). Le médicament est un anticorps monoclonal IgG1 entièrement humain ciblant les cellules exprimant CD38, avec le potentiel de devenir le meilleur de sa catégorie.
XOMA Royalty Corporation (NASDAQ: XOMA) hat die zukünftigen Lizenzgebühren- und Meilensteinrechte an Mezagitamab (TAK-079) von BioInvent International in einem Deal im Wert von bis zu 30 Millionen US-Dollar erworben. Die Transaktion umfasst eine Zahlung von 20 Millionen US-Dollar bei Vertragsabschluss und weitere 10 Millionen US-Dollar, die an die FDA-Zulassung von Mezagitamab zur Vermarktung bei IgA-Nephropathie gebunden sind.
Mit diesem Erwerb und den bestehenden Ansprüchen wird XOMA bis zu 16,25 Millionen US-Dollar an Meilensteinen von Takeda erhalten sowie mittlere einstellige Lizenzgebühren auf zukünftige kommerzielle Verkäufe von Mezagitamab. Takeda führt derzeit eine Phase-3-Studie mit Mezagitamab bei Patienten mit immunvermittelter Thrombozytopenie (ITP) durch. Das Medikament ist ein vollhumaner IgG1 monoklonaler Antikörper, der auf CD38-exprimierende Zellen abzielt und das Potenzial hat, die beste seiner Klasse zu werden.
- Acquisition increases XOMA's economic interest in a promising Phase 3 drug candidate
- Deal structure includes immediate $20M payment plus $10M milestone-based payment
- XOMA gains rights to future milestone payments of up to $16.25M from Takeda
- Company will receive mid-single digit royalties on future mezagitamab sales
- Mezagitamab shows potential to become best-in-class anti-CD38 monoclonal antibody
- Significant upfront capital expenditure of $20M required
- Additional $10M payment contingent on uncertain FDA approval
- Returns dependent on successful drug development and commercialization
Insights
XOMA's $30M royalty acquisition for Phase 3 mezagitamab strengthens late-stage portfolio while providing BioInvent non-dilutive capital.
XOMA has strategically consolidated its position in mezagitamab by acquiring BioInvent's royalty and milestone rights for up to
Mezagitamab is positioned as a potentially best-in-class anti-CD38 monoclonal antibody with high affinity for CD38-expressing cells. The compound has already advanced to Phase 3 clinical trials for immune thrombocytopenia (ITP), significantly derisking the investment compared to earlier-stage assets. The targeting of CD38-expressing cells, including plasmablasts and plasma cells, places mezagitamab in a clinically validated therapeutic class alongside successful drugs like Darzalex (daratumumab).
For BioInvent, this deal provides substantial non-dilutive capital at a critical time, allowing the company to advance its proprietary pipeline without issuing additional shares. The transaction also validates the value of BioInvent's n-CoDeR® antibody library platform technology, highlighting its ability to generate clinically relevant candidates with partnering potential.
This deal exemplifies XOMA's business model as a biotech royalty aggregator - acquiring economic interests in promising late-stage assets while avoiding the direct costs and risks of drug development. With mezagitamab now in Phase 3 for ITP and being evaluated for IgA nephropathy, XOMA has strategically increased its exposure to a compound approaching potential commercialization within a reasonable timeframe.
EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced XOMA Royalty has purchased the future mezagitamab (TAK-079) royalty and milestone interests held by BioInvent for USD
“This transaction further builds the potential of XOMA Royalty’s late-stage royalty portfolio by increasing our economics in a promising Phase 3 program already in our portfolio,” stated Brad Sitko, Chief Investment Officer of XOMA Royalty. “We appreciate the longstanding relationship with BioInvent stemming from XOMA’s legacy technology, which gave rise to mezagitamab. We are pleased to provide BioInvent non-dilutive capital to further advance its proprietary pipeline to a key inflection point.”
Martin Welschof, Chief Executive Officer of BioInvent said, “Today’s announcement highlights the value to BioInvent of our n-CoDeR® platform, which has led to the identification of multiple promising therapeutic antibody drug candidates, many of which are now in mid-to late-stage clinical trials. As well as reflecting XOMA Royalty’s expanded interest in mezagitamab, this transaction supports our strategy of creating value via partnerships and gives us a non-dilutive capital injection that bolsters our balance sheet so that we can continue to focus on advancing our own clinical drug development programs.”
The future royalty and milestone economics interest in mezagitamab originated from a 2003 cross-licensing agreement covering XOMA Royalty’s legacy bacterial protein expression technology and BioInvent’s n-CoDeR® antibody library. Under the terms of XOMA Royalty’s purchase of BioInvent’s economic interest in mezagitamab, XOMA Royalty paid USD
With its existing entitlement, plus the newly acquired economics from BioInvent, XOMA Royalty will be entitled to milestones of up to USD
In its Fiscal Year 2024 financial results, Takeda, the company developing mezagitamab, announced it has initiated a Phase 3 clinical trial in patients with immune thrombocytopenia (ITP)1. Mezagitamab is a fully human immunoglobulin IgG1 monoclonal antibody (mAb) with high affinity for CD38 expressing cells (including plasmablasts, plasma cells, natural killer cells) resulting in their depletion that has the potential of becoming the best-in-class anti-CD38 mAb2.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.
XOMA Royalty Forward-Looking Statements/Explanatory Notes
Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial and milestone payments to XOMA Royalty and other developments related to mezagitamab. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will”, “would,” “could” or “should,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA Royalty’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; and if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them. Other potential risks to XOMA Royalty meeting these expectations are described in more detail in XOMA Royalty's most recent filing on Form 10-Q and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA Royalty's prospects. Any forward-looking statement in this press release represents XOMA Royalty's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA Royalty disclaims any obligation to update any forward-looking statement, except as required by applicable law.
EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.
As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel
BioInvent disclaimer
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
| XOMA Royalty Investor contact: | XOMA Royalty Media contact: | |
| Juliane Snowden | Kathy Vincent | |
| XOMA Royalty Corporation | KV Consulting & Management | |
| +1-646-438-9754 | +1-310-403-8951 | |
| juliane.snowden@xoma.com | kathy@kathyvincent.com | |
BioInvent Investor Contact:
Cecilia Hofvander, VP Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No.: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
This information is information that BioInvent International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 2025-05-27 14:00 CEST (8:00 am EDT).
1 https://assets-dam.takeda.com/image/upload/v1746766844/Global/Investor/Financial-Results/FY2024/Q4/qr2024_q4_p01_en.pdf
2 https://assets-dam.takeda.com/image/upload/Global/Investor/events/2024/RD_Presentation_2024_EN.pdf
FAQ
What is the total value of XOMA's mezagitamab royalty rights acquisition from BioInvent?
What royalties will XOMA receive from mezagitamab sales?
What is the current development stage of mezagitamab (TAK-079)?
What is mezagitamab and how does it work?
How does this acquisition benefit BioInvent?
